Separately, Maxim Group set a $25.00 price objective on shares of Aridis Pharmaceuticals and gave the company a buy rating in a report on Thursday, May 16th.
Shares of Soligenix stock opened at $1.14 on Thursday. Soligenix has a 1 year low of $0.65 and a 1 year high of $2.20. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.20 and a quick ratio of 2.20. The business’s fifty day simple moving average is $0.79.
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Read More: Book Value Per Share – BVPS
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.